Dr. DeBerardinis receives 2019 Edith and Peter O’Donnell Award from The Academy of Medicine, Engineering and Science of Texas (TAMEST)
Dr. Ralph DeBerardinis is one of two UT Southwestern faculty members to receive a 2019 Edith and Peter O’Donnell Award from The Academy of Medicine, Engineering and Science of Texas (TAMEST). The O’Donnell Awards – honoring four researchers statewide this year – recognize outstanding achievements by Texas early career investigators in science, medicine, engineering, and technology innovation. Press Release
Dr. Timmerman receives ASTRO Fellow designation
Dr. Robert Timmerman, Professor and Vice Chair of the Department of Radiation Oncology, receives the ASTRO Fellow (FASTRO) designation. This designation is awarded based on ASTRO membership, service to ASTRO, and contributions to the field of radiation oncology.
Dr. James Chen receives 2019 Breakthrough Prize in Life Sciences
UTSW biochemist Dr. Zhijian (James) Chen is awarded the 2019 Breakthrough Prize in Life Sciences, the second UTSW faculty member to receive this prestigious award since its inception in 2013. The international award program is sponsored by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Ma Huateng, Yuri and Julia Milner, and Anne Wojcicki. Winners receive $3 million each. Press Release • Twitter
Team consensus on tumor margin annotation improves trial eligibility
Multidisciplinary team of pathologists and urologists arrives at a consensus for how to annotate renal cancer tumor margins using new nomenclature, resulting in improved quality control and broadening trial eligibility for patients.
Drs. Pedrosa and Brugarolas present at the 13th International VHL Medical/Research Symposium
Drs. Pedrosa and Brugarolas discuss their research, and Dr. Brugarolas participates in a panel discussion on management of localized kidney masses, at the 13th International VHL Medical/Research Symposium held in Houston, TX.
2018 KCP Annual Event brings together over 300 patients and guests to learn more about the program and about the latest in treatment options
The KCP Annual Event was held on September 30, 2018, on the 14th floor of the Pickens Biomedical Building. Over 300 patients, their guests, and KCP doctors were in attendance. A highlight of the event was the case presentation featuring Robert Wilonsky, reporter and journalist for the Dallas Morning News, and kidney cancer survivor. Story
New test uncovers metabolic vulnerabilities in kidney cancer
KCP researchers develop a novel approach using intraoperative infusions of labeled glucose to assess RCC tumor metabolism. These findings may open up new opportunities for therapeutic intervention. Press Release
UTSW scientists identify new mechanisms underlying pediatric kidney cancer
Kidney SPORE investigators Dr. Jim Amatruda and Dr. Josh Mendell report their follow-up studies on the role of microRNAs in Wilms tumor, the most common cancer of the kidney in children. In separate papers, Dr. Amatruda's group and Dr. Mendell's group report on different mechanisms of IGF2 regulation. Press Release
UTSW’s Kidney SPORE awards 8 recipients with DRP/CEP funding to support innovative kidney cancer research
Eight outstanding awardees will be supported as part of SPORE Year 3 Developmental Research and Career Enhancement Programs (DRP and CEP). The DRP awardees are: Drs. Srinivas Malladi, Chad Rethorst, and Tao Wang. CEP awards went to Drs. Alberto Diaz de Leon, Keri Drake, Nick Grishin, Jin Jiang, and Ram Mani. Research proposal topics ranged from identifying determinants of metastatic latency to whole body detection of osseous metastases to identifying the cell origin of Wilms tumor.
Two UT Southwestern investigators awarded $30K grants from Action to Cure Kidney Cancer
ACKC, a kidney cancer grassroots advocacy organization, donated funds to the KCP to award grants to attract new investigators to the kidney cancer field. The ACKC “fellows” are Sarah Huen, M.D., Ph.D., Assistant Professor in Internal Medicine, and Kiyoshi Ariizumi, Ph.D., Professor in Dermatology. Their proposals focus on cachexia and immunotherapy, respectively, in renal cell carcinoma.